



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:)
Garlich et al.) Before the Examiner
Application No. 10/573,938) Unknown
Filed March 30, 2006) Group Art Unit
CHELATE BASED SCAFFOLDS) Unknown
IN TUMOR TARGETING) August 31, 2006

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Commissioner:

1. List of All Patents, Publications, U.S. Applications, or Other Information

Pursuant to the provisions of 37 CFR 1.56, 1.97, and 1.98, Applicant requests consideration of the references listed on the attached PTO/SB/08 form(s) (commonly referred to as a PTO-1449 form) and/or the additional information identified below.

- ☒ I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as **first class mail** in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.
- ☐ I hereby certify that this correspondence is being deposited with the United States Postal Service as "**Express Mail** Post Office to Addressee" in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Mailing Label No. EV US, on the date indicated below.
- ☐ I hereby certify that this correspondence is being **facsimile transmitted** to the United States Patent and Trademark Office, Fax No. (571) 273-8300 on the date indicated below.

Edward E. Sowers
Typed/printed name of person signing this certificate

Edward E. Sowers
Signature

August 31, 2006
Date

2. Enclosed Legible Copies

- a. A legible copy of each foreign patent document and publication listed on the PTO/SB/08 form is enclosed,
- ☐ i. except, a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior U.S. Patent Application Serial No. _____, filed _____ from which the present application claims priority under 35 U.S.C. §120.
- ☐ ii. except, a copy is not provided for each cumulative reference and enclosed reference identified below:
- ☐ b. A copy of the specification and drawings for each cited unpublished U.S. application.
- ☐ c. A copy of a Search Report or Written Opinion from a foreign patent office is also enclosed.
- ☐ d. Consideration of the enclosed additional and/or below discussed information is requested.

3. Concise Explanation of Relevance for Non-English Language Information

For each non-English language reference listed on the attached SB/08 form(s), reference is made to:

- ☐ 3a. an English language translation submitted herewith,
- ☐ 3b. foreign patent office Search Report (in the English language) submitted herewith,
- ☐ 3c. an English language translation of a foreign patent office Search Report submitted herewith,
- ☐ 3d. the concise explanation contained in the present application at page(s) ____,
- ☐ 3e. the concise explanation set forth in the attached English language abstract,
- ☐ 3f. a copy of a related patent publication (in the English language) cited herewith,

Foreign Patent Document	Corresponding English Language Patent Document

- ☐ 3g. the following concise explanation: ____.

4. Time for Filing

- ☒ 4a. This Information Disclosure Statement is submitted:
- ☐ i. for U.S. national applications or national stage PCT applications (not including CPAs and RCEs), within 3 months of filing or entry into national stage; or

- ☒ ii. for U.S. national applications, national stage PCT applications, CPAs or RCEs, before the first Office Action on the merits,

and thus no certification and/or fee is required.

- ☐ 4b. This information Disclosure Statement is submitted after three months from the filing date and after the first Office Action on the merits, but prior to the mailing date of a final Office Action or Notice of Allowance, and thus:
- ☐ i. the statement specified in 37 CFR §1.97(e) is provided below, or
- ☐ ii. a fee of \$___ (set forth in 37 CFR §1.17(p)) is enclosed.
- ☐ 4c. This Information Disclosure Statement is submitted after the mailing date of a final Office Action or Notice of Allowance and prior to payment of the issue fee, and thus:
- ☐ i. the statement specified in 37 CFR §1.97(e) is provided below, and a fee of \$___ (set forth in 37 CFR §1.17(p)) is enclosed, or
- ☐ ii. a Request for Continued Examination (RCE) and fee of 37 CFR §1.17(e) has been filed.
- ☐ 4d. This Information Disclosure Statement is submitted after payment of the issue fee, and thus:
- ☐ i. a Petition to Withdraw from Issue pursuant to 37 CFR §1.313(c)(2) has been filed, and
- ☐ ii. a Request for Continued Examination (RCE) and fee of 37 CFR §1.17(e) has been filed.

5. Certification- Statement Under 37 CFR 1.97(e)

- ☐ 5a. It is hereby certified that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- ☐ 5b. A copy of a dated communication from a foreign patent office which clearly shows the statement is being submitted within three (3) months of the date on the communication is enclosed.
- ☐ 5c. It is hereby certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.


The filing of this Information Disclosure Statement shall not be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in §1.56(b). It is

believed that no additional fees are required. Should any other fee be required, however, please charge such fee to Deposit Account No. 23-3030, but not to include any payment of issue fees.

Respectfully submitted,

By Edward E. Sowers
Edward E. Sowers, Reg. No. 36,015
Woodard, Emhardt, Moriarty, McNett & Henry LLP
111 Monument Circle, Suite 3700
Indianapolis, Indiana 46204-5137
(317) 634-3456

417228



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/573,938
Filing Date	March 30, 2006
First Named Inventor	Joseph R. Garlich
Group Art Unit	
Examiner Name	

Attorney Docket Number 48003-5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²
		TAI-PING D. FAN, RHYS JAGGAR and ROY BICKNELL – Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy;	
		JUDAH FOLKMAN – Angiogenesis in cancer, vascular, rheumatoid and other diseases; Nature Medicine, Volume 1, Number 1 1995	
		J. MARTIN BROWN and AMATO J. GIACCIA – The Unique Physiology of Solid Tumors: Opportunities (and Problems) for Cancer Therapy; Cancer Research 58, 1408-1416, April 1, 1998	
		BRAD ST. CROIX, CARLO RAGO, VICTOR VELCULESCU, GIOVANNI TRAVERSO, KATHARINE E. ROMANS, ELIZABETH MONTGOMERY, ANITA LAL, GREGORY J. RIGGINS, CHRISTOPH LENGAUER, BERT VOGELSTEIN, KENNETH W. KINZLER – Genes Expressed in Human Tumor Endothelium; Science; 08/18/2000, Vol. 289 Issue 5482, p1197, 6p, 1 graph, 2c	
		STEPHEN J. KENNEL and SAED MIRZADEH – Vascular Targeted Radioimmunotherapy with ²¹³ Bi-An α –Particle Emitter; Nuclear Medicine & Biology, Vol. 25, pp. 241-246, 1998	
		STEVEN DICKMAN – Antibodies Stage a Comeback in Cancer Treatment; Science; 05/22/98, Vol. 280 Issue 5367, p1196, 2p, 1 graph, 1bw	
		MARCIA BARINAGA – A Surprising Partner for Angiostatin; Science; 03/19/99, Vol. 283 Issue 5409, p1831, 5/6p, 1c	
		WADIH ARAP, RENATA PASQUALINI, ERKKI RUOSLAHTI – Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model; Science Vol. 279, January 16, 1998	
		RENATA PASQUALINI, ERKKI KOIVUNEN, ERKKI RUOSLAHTI – α v Integrins as receptors for tumor targeting by circulating ligands; Nature Biotechnology, Volume 15, June 1997	
		WADIH ARAP, RENATA PASQUALINI, ERKKI RUOSLAHTI – Chemotherapy targeted to tumor vasculature; Cancer Research Center, The Burnham Institute	
		RENATA PASQUALINI – Vascular targeting with phage peptide libraries; The Quarterly Journal of Nuclear Medicine, Vol. 43, No. 2	
		D. BLOK et al. – Peptide radiopharmaceuticals in nuclear medicine; European Journal of Nuclear Medicine, Vol. 26, No. 11, November 1999	
		WYNN A. VOLKERT, TIMOTHY J. HOFFMAN – Therapeutic Radiopharmaceuticals; 1999 Am. Chem. Soc. Published on Web 8/11/1999	
		KARL GADEMANN, MARTIN ERNST, DANIEL HOYER, DIETER SEEBACH – Synthesis and Biological Evaluation of a Cyclo-β-tetrapeptide as a Somatostatin Analogue; Angew. Chem. Int. Ed. 1999, 38, No. 9	

Examiner
SignatureDate
Considered

Substitute for form 1449B/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/573,938
Filing Date	March 30, 2006
First Named Inventor	Joseph R. Garlich
Group Art Unit	
Examiner Name	

Sheet	2	of	4	Attorney Docket Number	48003-5
-------	---	----	---	------------------------	---------

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²
		RALPH HIRSCHMANN, K.C. NICOLAOU, SHERRIE PIETRANICO, JOSEPH SALVINO, ELLEN M. LEAHY, PAUL A. SPRENGELER, GEORGE FURST, AMOS B. SMITHIII, CATHERINE D. STRADER, MARGARET A. CASCIERI, MARIALUISA R. CANDELORE, CINDY DONALDSON, WYLIE VALE, LAURIE MAECHLER – Nonpeptidal peptidomimetics with a β -D-Glucose Scaffolding. A Partial Somatostatin Agonist Bearing a Close Structural Relationship to a Potent, Selective Substance P Antagonist; 1992 Am Chem. Society	
		K. C. NICOLAOU, JOHN I. TRUJILLO, KELLY CHIBALE – Design, Synthesis and Biological Evaluation of Carbohydrate-Based Mimetics of cRGDFV; Tetrahedron, Vol. 53, No. 26, pp. 8751-8778, 1997	
		MARK W. PECZUH, ANDREW D. HAMILTON – Peptide and Protein Recognition by Designed Molecules; 2000 Am. Chem. Soc., Published on Web 06/20/2000	
		ROLAND HAUBNER, HANS-JURGEN WESTER, UTE REUNING, REINGARD SENKOWITSCH-SCHMIDTKE, BEATE DIEFENBACH, HORST KESSLER, GERHARD STOCKLIN, MARKUS SCHWAIGER; Radiolabeled $\alpha_v\beta_3$ Integrin Antagonists: A New Class of Tracers for Tumor Targeting; J Nucl Med 1999; 40:1061-1071	
		B.R. LINE, P. WEBER, S. WURTHMAN, M. SALGAM, J.A. BENNETT – Intravascular Targeting of Tumor Angiogenesis Via TC-99M Radiolabeled Peptide Antagonists of the $\alpha_v\beta_3$ Integrin; Journal of Nuclear Medicine, Scientific Papers, Volume 40, Number 5, May 1999 Supp.	
		RICHARD M. KEENAN, WILLIAM H. MILLER, CHET KWON, FADIA E. ALI, JAMES F. CALLAHAN, RAUL R. CALVO, SHING-MEI HWANT, KENNETH D. KOPPLE, CATHERINE E. PEISHOFF, JAMES M. SAMANEN, ANGELA S. WONG, CHUAN-KUI YUAN, WM. F. HUFFMAN – Discovery of Potent Nonpeptide Vitronectin Receptor ($\alpha_v\beta_3$) Antagonists; 1997 Am. Chem Society, Volume 40, Number 15	
		CHRISTOPHER P. CARRON, DEBRA M. MEYER, JODI A. PEGG, V. WAYNE ENGLEMAN, MAUREEN A. NICKOLS, STEVEN L. SETTLE, WM. F. WESTLIN, PETER G. RUMINSKI, G. ALLEN NICKOLS – A Peptidomimetic Antagonist of the Integrin $\alpha_v\beta_3$ Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy; Cancer Research 58, 1930-1935, May 1, 1998	
		R. HAUBNER et al. – Synthesis and First Evaluation of a SAA-Labeled RGD-Peptide for Monitoring the $\alpha_v\beta_3$ Integrin Expression; Journal of Nuclear Medicine, Sunday June 4, 2000	
		M. BOCK et al. – ^{99m} Tc-, ¹⁸⁸ Re- AND ⁹⁰ Y-Labeled $\alpha_v\beta_3$ Antagonists: Promising Tracer For Tumor Induced Angiogenesis; Journal of Nuclear Medicine, Volume 41, Number 5, 5/2000 Supp.	
		ANGELA WONG, SHING MEI HWANG, PATRICK MCDEVITT, DEAN MCNULTY, JEFFREY M. STADEL, KYUNG JOHANSON – Studies on $\alpha_v\beta_3$ Ligand Interactions Using a [³ H]SK&F-107260 Binding Assay; Am. Soc. for Pharmacology and Experimental Therapeutics	

Examiner
SignatureDate
Considered

Substitute for form 1449B/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

4

Attorney Docket Number

48003-5

Application Number

10/573,938

Filing Date

March 30, 2006

First Named Inventor

Joseph R. Garlich

Group Art Unit

Examiner Name

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²
		PETER CARAVAN, JEFFREY J. ELLISON, THOMAS J. MCMURRY, RANDALL B. LAUFFER – Gadolinium (III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications; 1999 Am. Chem. Society, Published on Web 08/20/1999	
		A.K. RAPPE, C.J. CASEWIT, K.S. COLWELL, W.A. GODDARD III, W.M. SKIFF – UFF, a Full Periodic Table Force Field for Molecular Mechanics and Molecular Dynamics Simulations; 1992 Am. Chem. Society, 114, 10024-10035	
		MARTIN J. O'DONNELL, CHANGYOU ZHOU, WM. L. SCOTT – Solid-Phase Unnatural Peptide Synthesis (UPS); J. Am. Chem Soc. 1996, 118, 6070-6071	
		WM. F. SCOTT, CHANGYOU ZHOU, ZHIQIANG FANG, MARTIN J. O'DONNELL – The Solid Phase Synthesis of α,α -Disubstituted Unnatural Amino Acids and Peptides (di-UPS); Tetrahedron Letters, Vol. 38, No. 21, pp. 3695-3698, 1997	
		DAVID L. GRIFFITH, MARTIN J. O'DONNELL, RICHARD S. POTTORF, WM. L. SCOTT, JOHN A. PORCO, JR. – Tandem UPS: Sequential Mono- and Dialkylation of Resin-Bound Glycine via Automated Synthesis; Tetrahedron Letters, Vol. 38, No. 51, pp. 8821-8824, 1997	
		MARTIN J. O'DONNELL, FRANCISCA DELGADO, RICHARD S. POTTORF – Enantioselective Solid-Phase Synthesis of α -Amino Acid Derivatives; Tetrahedron 55 (1999) 6347-6362	
		STU BORMAN – Multivalency: Strength in Numbers; Chemical & Engrg. News: Volume 78, Number 41, October 9, 2000	
		MATHAI MAMMEN, SEOK-KI CHOI, GEORGE M. WHITESIDES – Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors; Angew. Chem. Int. Ed. 1998, 37, 2754-2794	
		KEVIN BURGESS, DONGYEOL LIM, SHAKER A. MOUSA – Synthesis and Solution Conformation of Cyclo: A Cyclic Peptide with Selectivity for the $\alpha_v\beta_3$ Receptor; 1996 Am. Chem. Society, October 1, 1996, 4520-4526	
		KEITH ROSE and JEAN VIZZAVONA – Stepwise Solid-Phase Synthesis of Polyamides as Linkers; J. Am Chem. Soc. 1999, 121, 7034-7038	
		ERKANG FAN, ZHONGSHENG ZHANG, WENDY E. MINKE, ZHENG HOU, CHRISTOPHE L.M.J. VERLINDE, WIM G.J. HOL – High-Affinity Pentavalent Ligands of <i>Escherichia coli</i> Heat-Labile Enterotoxin by Modular Structure-Based Design; J. Am Chem Soc. 2000, 122, 2663-2664	
		PAVEL I. KITOV ET AL. – Shiga-Like toxins are neutralized by tailored multivalent carbohydrate ligands; Nature, Volume 403, 10 Feb. 2000	
		JEFFREY W. SMITH, DAVID A. CHERESH – The Arg-Gly-Asp Binding Domain of the Vitronectin Receptor; Journal of Biological Chemistry, Vol. 263, No. 35, 12/15/1988, pp. 18726-18731	
		FRANCESCO MITJANS et al. – An anti- α_v integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice; Journal of Cell Science 108, 2825-2838 (1995)	
		ROBERT PYTELA et al. – Platelet Membrane Glycoprotein IIb/IIIa: Member of a Family of Arg-Gly-Asp-Specific Adhesion Receptors; Science Vol. 231, March 28, 1986	

Examiner
SignatureDate
Considered

Complete if Known

Application Number	10/573,938
Filing Date	March 30, 2006
First Named Inventor	Joseph R. Garlich
Group Art Unit	
Examiner Name	

(use as many sheets as necessary)

Sheet 4 of 4 Attorney Docket Number 48003-5

[illegible]

Examiner
Signature

Date
Considered